Tenax Therapeutics Inc

Quantli Newsdesk

· 5 days ago

Tenax Therapeutics reported that its Phase 3 LEVEL trial of TNX-103 in patients with pulmonary hypertension associated with heart failure failed to demonstrate statistically significant improvement in exercise capacity or symptom measures. The company now plans to seek FDA guidance on revising its development strategy based on subgroup findings suggesting benefit in more severely affected patients.